First patient dosed in phase 1b/2a trial for castration-resistant metastatic prostate cancer, evaluating pocenbrodib alone ...

The future of Johnson & Johnson's cancer blockbuster Zytiga is in doubt, after a US patent ruling has opened the door to generic competitors. Johnson & Johnson’s Q4 results were hit by a one-off ...

The plant will make three types of insulin, which Civica has pledged to sell for $30 a vial and $55 for a box of five pens.

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Zytiga is one of the most important growth products for J&J, with worldwide sales of the drug in the first half of the year growing more than 38 per cent to reach $464m. Link NICE says no to early ...

In a live event, Ganesh V. Raj, MD, PhD, discussed the drug-drug interactions and outcomes by disease volumes across ARPI trials in mHSPC.

In a mouse model of prostate cancer, the RIPTAC outperforms enzalutamide, the androgen biosynthesis inhibitor abiraterone (Zytiga) and Arvinas’s first-generation and now-discontinued AR-degrader ...

Adding an immune checkpoint inhibitor (ICI) to chemotherapy for advanced prostate cancer failed to improve survival as ...

Zytiga treats metastatic prostate cancer by reducing male hormone production, slowing tumor growth. The drug is FDA-approved for both hormone-resistant and hormone-sensitive metastatic prostate cancer ...

The first patient has been dosed in a phase 1b/2a trial (NCT06785636) of pocenbrodib, a CBP/p300 inhibitor, as a monotherapy and in combination with abiraterone acetate (Zytiga), olaparib (Lynparza), ...